Association of DNA methylation, polymorphism and mRNA level of ALAS1 with antituberculosis drug-induced liver injury

2024-9-12

Evaluation of pharmacogenetic automated clinical decision support for clopidogrel

2024-9-11

Accuracy and technical characteristics of CYP2C19 point of care tests: a systematic review

2024-9-4

It is time for educators to act: pharmacogenomics education and its implementation into clinical practice

2024-9-4

Meta-analysis revisiting the influence of <i>UGT1A1*28</i> and <i>UGT1A1*6</i> on irinotecan safety in colorectal cancer patients

2024-8-22

Update on the PriME-PGx initiative: evolution of pharmacogenetics in daily clinical practice

2024-8-8

Implementing pharmacogenomic testing in Australian general practice: an exploratory qualitative study

2024-8-7

Pharmacogenetics of Calcineurin inhibitors in kidney transplant recipients: the African gap. A narrative review

2024-8-7

Potential association of <i>SULT2A1</i> and <i>ABCG2</i> variant alleles with increased risk for palbociclib toxicity

2024-8-2

Impact of IL-6 and IL-10 genotypes on tacrolimus dose requirements in kidney transplant recipients: Monte Carlo analysis

2024-7-29

Correlation of <i>ACE</i> insertion/deletion gene polymorphism with captopril effectiveness in Indonesian hypertensive patients

2024-7-29

Rapid point of care testing: the next frontier in pharmacogenomics

2024-7-23

Genotype-guided prescribing predictors in CYP2C19 intermediate metabolizers receiving percutaneous coronary intervention

2024-6-6

A critical review of RAF inhibitors in BRAF-mutated glioma treatment

2024-6-3

Impact of <i>CYP2D6</i> and <i>ADRB1</i> polymorphisms on heart rate of post-PCI patients treated with metoprolol

2024-5-31

Screening and analysis of single nucleotide polymorphism in the 3′-UTR microRNA target regions and its implications for lung tumorigenesis

2024-5-30

SALL4 upregulates brain-derived neurotrophic factor to mediate Hedgehog signaling to inhibit carboplatin sensitivity in colon adenocarcinoma

2024-5-22

Influence of genetic polymorphisms on pharmacokinetics and treatment response of mycophenolic acid: a scoping review

2024-5-17

Genetic diversity of cytochrome P450 in patients receiving psychiatric care in Greece: a step towards clinical implementation

2024-5-15

Polymorphism of <i>CYP3A4*18</i> is associated with anti-tuberculosis drug-induced hepatotoxicity

2024-5-13

The cost–effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma

2024-5-13

Erratum

2024-5-9

Pharmacogenomic implications of the differential distribution of CYP3A5 metabolic phenotypes among Latin American populations

2024-3-1

Knowledge and perceptions of pharmacogenomics among pharmacists in Manitoba, Canada

2024-3-1

Pharmacogenomics for Prader-Willi syndrome: caregiver interest and planned utilization

2024-3-1

Implementation of whole-exome sequencing for pharmacogenomics profiling and exploring its potential clinical utilities

2024-3-1

The genomic landscape of <i>CYP2D6</i> variation in the Indian population

2024-3-1

Ethnic differences in pharmacogenomic variants: a south Asian perspective

2024-3-1

<i>MIR27A</i> rs895819 TC genotype increases risk of fluoropyrimidine-induced severe toxicity independently of <i>DPYD</i> variations

2024-2-14

Workforce readiness for pharmacogenomics and key elements for sustainment within the Veterans Health Administration

2024-2-1

Targeting RET mutation in medullary thyroid cancer

2024-2-1

Genetic risk factors for drug-induced long QT syndrome: findings from a large real-world case–control study

2024-2-1

<i>PIK3CA</i> testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories

2024-2-1

Association between <i>CYP3A4</i>, <i>CYP3A5</i> and <i>ABCB1</i> genotype and tacrolimus treatment outcomes among allogeneic HSCT patients

2024-1-1

Assessing the utility of measurement methods applied in economic evaluations of pharmacogenomics applications

2024-1-1

Antiplatelet Therapy Guided by <i>CYP2C19</i> Point-of-Care Pharmacogenetics Plus Multidimensional Treatment Decisions

2024-1-1

Psychiatric Level 1A evidence pharmacogenomics in a Brazilian admixed cohort and global populations

2024-1-1

Update on <i>HLA-B*15:02</i> allele associated with adverse drug reactions

2024-1-1

Pharmacogenetic and pharmacogenomic treatment of rheumatoid arthritis: a review of Pharmacogenomics Knowledge Base scientific evidence

2024-1-1

Relevance of <i>NAT2</i> genotype and clinical factors to risk for antituberculosis drug-induced liver injury

2023-12-22

Epigenetic regulation of drug metabolism in aging: utilizing epigenetics to optimize geriatric pharmacotherapy

2023-12-21

Overview of the year 2023 at <i>Pharmacogenomics</i>

2023-12-19

<i>SLCO1B1</i> variants and the risk of antituberculosis drug-induced hepatotoxicity: a systematic review and meta-analysis

2023-12-1

Pharmacogenomic testing in oncology: a health system's approach to identify oncology provider perspectives

2023-11-1

Characterization of <i>CYP2C19</i> pharmacogenetic variation in African populations and comparison with other global populations

2023-11-1

Pharmacogenomics Implementation Across Multiple Clinic Settings: A Qualitative Evaluation

2023-11-1

Clinical pharmacology and pharmacogenomics for implementation of personalized medicine

2023-11-1

Towards more accurate pharmacogenomic variant effect predictions

2023-10-17

Pharmacogenomic Variants Affecting Efficacy and Toxicity of Statins in a South Asian Population from Sri Lanka

2023-10-1

Pharmacogenomics of Chloroquine and Hydroxychloroquine: Current Evidence and Future Implications

2023-10-1